The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside

[1]  K. Ogan,et al.  Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Anthony Patterson,et al.  Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  P. Agarwal,et al.  Current clinical trials in non-muscle invasive bladder cancer. , 2017, Urologic oncology.

[4]  D. Lamm,et al.  An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. , 2017, Urologic oncology.

[5]  D. Lamm,et al.  BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG , 2017, Nature Reviews Urology.

[6]  N. Brook,et al.  Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. , 2017, The Cochrane database of systematic reviews.

[7]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[8]  John D Seigne,et al.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.

[9]  Ryan L. Steinberg,et al.  Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease , 2016, Bladder cancer.

[10]  C. Klingler,et al.  Glycosaminoglycans: How Much do We Know about their Role in the Bladder? , 2016, Urologia.

[11]  R. Pazdur,et al.  Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer , 2015, Bladder cancer.

[12]  J. Maranchie,et al.  The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer , 2015, Advances in urology.

[13]  C. Dinney,et al.  Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG , 2015, Bladder cancer.

[14]  B. Baldo.  Side Effects of Cytokines Approved for Therapy , 2014, Drug Safety.

[15]  M. Havenga,et al.  Challenges in manufacturing adenoviral vectors for global vaccine product deployment. , 2014, Human gene therapy.

[16]  C. Dinney,et al.  Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a Phase l study , 2014, Cancer Gene Therapy.

[17]  P. Schlag,et al.  Current status of gene therapy for cancer , 2013, Current opinion in oncology.

[18]  C. Dinney,et al.  Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. , 2013, Urologic oncology.

[19]  C. Dinney,et al.  Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. , 2013, The Journal of urology.

[20]  T. Wirth,et al.  History of gene therapy. , 2013, Gene.

[21]  W. Shipley,et al.  Bladder cancer , 2009, The Lancet.

[22]  W. Benedict,et al.  Conditioned medium from Ad-IFN-α-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect , 2008, Cancer Gene Therapy.

[23]  C. Dinney,et al.  Interferon-α Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells , 2007 .

[24]  W. Benedict,et al.  Adenoviral-mediated interferon α overcomes resistance to the interferon protein in various cancer types and has marked bystander effects , 2007, Cancer Gene Therapy.

[25]  Brian J. Smith,et al.  Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. , 2006, Urologic oncology.

[26]  C. Dinney,et al.  Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation , 2006, Cancer Gene Therapy.

[27]  H. Woo,et al.  Management of stage T1 tumors of the bladder: International Consensus Panel. , 2005, Urology.

[28]  R. Connor,et al.  Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. , 2005, Urology.

[29]  A. Mackiewicz,et al.  Human cancer gene therapy with cytokine gene-modified cells , 2004, Expert opinion on biological therapy.

[30]  C. Dinney,et al.  Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein , 2004 .

[31]  B. Wiedenmann,et al.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. , 2003, Journal of the National Cancer Institute.

[32]  E. Kaasinen,et al.  Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results. , 2002, The Journal of urology.

[33]  B. Czerniak,et al.  Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer , 2002, Cancer Gene Therapy.

[34]  P. Malmström.  A randomized comparative dose‐ranging study of interferon‐α and mitomycin‐C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder , 2002, BJU international.

[35]  C. Dinney,et al.  Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  G. Demers,et al.  Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers , 2001, Cancer Gene Therapy.

[37]  J. Leiden,et al.  Gene and stem cell therapies. , 2001, JAMA.

[38]  E. Jonasch,et al.  Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. , 2001, The oncologist.

[39]  R. Bahnson,et al.  Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. , 2000, The Journal of urology.

[40]  R. Bahnson,et al.  EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER , 2000 .

[41]  C. Dinney,et al.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  R. Connor,et al.  Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents. , 1999, Urology.

[43]  A. Belldegrun,et al.  Superficial bladder cancer: the role of interferon-alpha. , 1998, The Journal of urology.

[44]  C. Bucana,et al.  Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. , 1998, Cancer research.

[45]  D. Curiel,et al.  Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. , 1995, Cancer gene therapy.

[46]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[47]  J. Hannigan,et al.  Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Loening,et al.  Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. , 1983, The Journal of urology.

[49]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[50]  D. Lamm,et al.  Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. , 2014, Urologic oncology.

[51]  C. Dinney,et al.  Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  A. Böhle.  Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study - Finnbladder III long-term results. , 2002, International braz j urol : official journal of the Brazilian Society of Urology.

[53]  H. Engler,et al.  Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium , 2001, Gene Therapy.

[54]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.